EUVIMEDEUVIMED entdecken
Crossref

A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma

Sidi Zhang, Hanyao Guo, Hongyu Wang, Xiaopeng Liu, Meixia Wang, Xiaoyu Liu, Yumei Fan, Ke Tan

Apoptosis · 2024

DOI: 10.1007/s10495-024-01945-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, 2024. Verfasst von Sidi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Collaborative Innovation Center for Eco-Environment, Hebei Research Cen…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Unfolded Protein Response, Sorafenib. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Innovation and Entrepreneurship Training Program for Undergraduates, Guiding Funds of Central Government for Supporting the Development of the Local Science and Technology, Hebei Province Higher Education Scientific Research Special Task Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a common cause of cancer-associated death worldwide. The mitochondrial unfolded protein response (UPRmt) not only maintains mitochondrial integrity but also regulates cancer progression and drug resistance. However, no study has used the UPRmt to construct a prognostic signature for HCC. This work aimed to establish a novel signature for predicting patient prognosis, immune cell infiltration, immunotherapy, and chemotherapy response based on UPRmt-related genes (MRGs). Transcriptional profiles and clinical information were obtained from the TCGA and ICGC databases. Cox regression and LASSO regression analyses were applied to select prognostic genes and develop a risk model. The TIMER algorithm was used to investigate immunocytic infiltration in the high- and low-risk subgroups. Here, two distinct clusters were identified with different prognoses, immune cell infiltration statuses, drug sensitivities, and response to immunotherapy. A risk score consisting of seven MRGs (HSPD1, LONP1, SSBP1, MRPS5, YME1L1, HDAC1 and HDAC2) was developed to accurately and independently predict the prognosis of HCC patients. Additionally, the expression of core MRGs was confirmed by immunohistochemistry (IHC) staining, single-cell RNA sequencing, and spatial transcriptome analyses. Notably, the expression of prognostic MRGs was significantly correlated with sorafenib sensitivity in HCC and markedly downregulated in sorafenib-treated HepG2 and Huh7 cells. Furthermore, the knockdown of LONP1 decreased the proliferation, invasion, and migration of HepG2 cells, suggesting that upregulated LONP1 expression contributed to the malignant behaviors of HCC cells. To our knowledge, this is the first study to investigate the consensus clustering algorithm, prognostic potential, immune microenvironment infiltration and drug sensitivity based on the expression of MRGs in HCC. In summary, the UPRmt-related classification and prognostic signature could assist in determining the prognosis and personalized therapy of HCC patients from the perspectives of predictive, preventative and personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsUnfolded Protein ResponseSorafenibImmunotherapyMitochondriaHumansPrognosisGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmMaleBiomarkers, TumorAntineoplastic AgentsFemaleCell Line, Tumor

Stichwörter der Autor:innen

Drug sensitivityHepatocellular carcinomaImmune microenvironmentMitochondrial unfolded protein response (UPRmt)Molecular subtypes

Substanzen

SorafenibBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Collaborative Innovation Center for Eco-Environment, Hebei Research Center of the Basic Discipline of Cell Biology, Hebei Key Laboratory of A…
  • Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Förderung

  • Innovation and Entrepreneurship Training Program for Undergraduates
  • Guiding Funds of Central Government for Supporting the Development of the Local Science and Technology
  • Hebei Province Higher Education Scientific Research Special Task Project

Zitieren

APA

Zhang, S., Guo, H., Wang, H., Liu, X., Wang, M., Liu, X., Fan, Y., & Tan, K. (2024). A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma. Apoptosis. https://doi.org/10.1007/s10495-024-01945-6

Vancouver

Zhang S, Guo H, Wang H, Liu X, Wang M, Liu X, et al. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma. Apoptosis. 2024. doi:10.1007/s10495-024-01945-6

BibTeX
@article{Zhang2024,
  author = {Zhang, Sidi and Guo, Hanyao and Wang, Hongyu and Liu, Xiaopeng and Wang, Meixia and Liu, Xiaoyu and Fan, Yumei and Tan, Ke},
  title = {A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma},
  journal = {Apoptosis},
  year = {2024},
  doi = {10.1007/s10495-024-01945-6}
}
Kostenlos starten →